FDA: New Draft Guidance on Impurity Specifications for Antibiotics
The US FDA has issued a new draft guidance on Impurity Specifications for Antibiotics.
Similar to the long-standing EMA guideline (EMA/CHMP/CVMP/QWP/199250/2009), the FDA draft focuses on fermentation-derived and semi-synthetic antibiotics. It applies the principles of ICH Q3A(R), ICH Q3B(R2) and ICH M7(R2) to the more complex impurity profile of these products.
Key Features of the FDA Draft
🔹 Three regulatory
pathways with tailored recommendations:
NDA (New Drug Applications), ANDA (abbreviated new drug applications) and OTC
monograph drugs
🔹 Nitrosamine risk assessment explicitly included
🔹 Comparative approach vs. the Reference Listed Drug (RLD) formally accepted for generics
🔹 Non-retroactive implementation, supporting supply continuity
Comment period closes: 22 June 2026.
Sources:
FDA: Establishing Impurity Specifications for Antibiotics
Dalia Global: News on LinkedIn
Meet the GMP Compliance Adviser
The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.
The demo access is non-binding and ends automatically.
You may also be interested in the following articles:
